华兰生物
(002007)
| 流通市值：291.74亿 | | | 总市值：339.06亿 |
| 流通股本：15.74亿 | | | 总股本：18.29亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 787,309,418.97 | 5,341,872,557.46 | 3,912,970,763.44 | 1,585,241,916.69 |
| 营业收入 | 787,309,418.97 | 5,341,872,557.46 | 3,912,970,763.44 | 1,585,241,916.69 |
| 二、营业总成本 | 544,582,536.78 | 3,424,990,839.29 | 2,542,889,952.52 | 1,100,616,603.42 |
| 营业成本 | 348,950,838.18 | 1,624,478,237.52 | 1,188,103,706.23 | 639,264,408.27 |
| 税金及附加 | 8,366,164.78 | 44,623,343.92 | 33,494,200.73 | 20,482,722.82 |
| 销售费用 | 44,727,602.74 | 1,202,428,525.24 | 893,755,342.73 | 159,380,059.29 |
| 管理费用 | 72,757,439.48 | 274,288,489.62 | 207,738,099.99 | 133,604,267.89 |
| 研发费用 | 72,713,577.15 | 280,843,979.31 | 217,858,152.48 | 145,266,820.38 |
| 财务费用 | -2,933,085.55 | -1,671,736.32 | 1,940,450.36 | 2,618,324.77 |
| 其中:利息费用 | 4,503,333.34 | 13,172,369.79 | 12,397,970.73 | 8,929,990.77 |
| 其中:利息收入 | 7,670,193.22 | 15,425,637.26 | 10,789,543.94 | 6,717,295.61 |
| 加:公允价值变动收益 | 9,462,052.83 | 60,544,227.95 | 47,474,465.22 | 35,321,806.08 |
| 加:投资收益 | 34,260,128.01 | 149,045,587.36 | 110,157,984.82 | 77,430,398.19 |
| 资产处置收益 | 74,937.31 | 44,443,673.01 | 43,648,059.73 | 43,601,783.04 |
| 资产减值损失(新) | - | -90,878,652.81 | 4,041,679.17 | 4,041,679.17 |
| 信用减值损失(新) | 33,924,838.11 | -13,923,571.52 | -25,733,535.37 | 40,675,107.64 |
| 其他收益 | 10,681,292.63 | 32,277,222.01 | 16,907,918.02 | 12,756,582.4 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 331,130,131.08 | 2,098,390,204.17 | 1,566,577,382.51 | 698,452,669.79 |
| 加:营业外收入 | 240,241.27 | 257,306.51 | 949,184.48 | 935,856.4 |
| 减:营业外支出 | 2,995,280.4 | 21,004,842.29 | 17,023,021.81 | 11,517,059.76 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 328,375,091.95 | 2,077,642,668.39 | 1,550,503,545.18 | 687,871,466.43 |
| 减:所得税费用 | 54,003,227.96 | 315,957,773.72 | 278,222,727.88 | 125,766,327.17 |
| 六、净利润 | 274,371,863.99 | 1,761,684,894.67 | 1,272,280,817.3 | 562,105,139.26 |
| 持续经营净利润 | 274,371,863.99 | 1,761,684,894.67 | 1,272,280,817.3 | 562,105,139.26 |
| 归属于母公司股东的净利润 | 261,773,937.6 | 1,481,578,849.25 | 1,067,286,160.09 | 526,652,592.9 |
| 少数股东损益 | 12,597,926.39 | 280,106,045.42 | 204,994,657.21 | 35,452,546.36 |
| (一)基本每股收益 | 0.14 | 0.81 | 0.59 | 0.29 |
| (二)稀释每股收益 | 0.14 | 0.81 | 0.59 | 0.29 |
| 九、综合收益总额 | 274,371,863.99 | 1,761,684,894.67 | 1,272,280,817.3 | 562,105,139.26 |
| 归属于母公司股东的综合收益总额 | 261,773,937.6 | 1,481,578,849.25 | 1,067,286,160.09 | 526,652,592.9 |
| 归属于少数股东的综合收益总额 | 12,597,926.39 | 280,106,045.42 | 204,994,657.21 | 35,452,546.36 |
| 公告日期 | 2024-04-26 | 2024-03-30 | 2023-10-30 | 2023-08-24 |
| 审计意见(境内) | | 标准无保留意见 | | |